References
Kremer Hovinga JA, Meyer SC. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2008;15(5):445–50. doi:10.1097/MOH.0b013e328309ec62.
Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11–8. doi:10.1182/blood-2008-02-078170.
Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28(3):385–91. doi:10.1006/bcmd.2002.0522.
Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71(2):105–8. doi:10.1002/ajh.10204.
Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005;81(5):433–6. doi:10.1532/IJH97.04187.
Rüfer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lämmle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly. 2007;137(37–38):518–24.
Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23(5):151–6. doi:10.1002/jca.20172.
Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. doi:10.1111/j.1365-2141.2006.06448.x.
Cataland SR, Wu HM. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. Expert Opin Pharmacother. 2007;8(4):437–44. doi:10.1517/14656566.8.4.437.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Scaramucci, L., Niscola, P., Palumbo, R. et al. Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura. Int J Hematol 89, 398–399 (2009). https://doi.org/10.1007/s12185-009-0274-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0274-9